CONNECT WITH US
HealthTech

HealthTech

After years-long turnaround, Convatec’s new CEO plans R&D push

MedTech Dive logo

Published on

Add as a preferred source on Google
After years-long turnaround, Convatec’s new CEO plans R&D push

Jonny Mason, who became CEO of the medtech firm a year ago following the death of Karim Bitar, said Convatec’s pace of launching new devices has accelerated for 2026 and 2027.

As Convatec completes a multiyear effort to turn around the business, new CEO Jonny Mason plans to invest in research and development for future growth.

The London-based medtech firm, which specializes in infusion care, wound care, ostomy care and continence, announced plans last year to expand its Boston-based R&D facility by 50%, and open a new facility in Manchester, England.

Former CEO Karim Bitar joined Convatec in 2019 to develop a turnaround strategy for the company, which had struggled with profit warnings and a falling share price since it started trading on the London Stock Exchange. That plan involved focusing on Convatec’s strengths, doubling its R&D investment and upping capital spending to rebuild its factories. Unfortunately, Bitar died suddenly last October while on medical leave.

Mason, who joined Convatec in 2022 as CFO, has taken on Bitar’s legacy after being named CEO in October. The turnaround is complete, Mason said, and Convatec is now aiming for sales growth of 6% to 8% next year, supported by a series of new product launches in each of its categories.

MedTech Dive spoke with Mason about what’s next for the company and its investment plans.
Editor’s note: This interview has been edited for length and clarity.

JONNY MASON: Something has changed, which is that we've increased our ambition. Karim very successfully took us through the turnaround strategy, and we acknowledged that the turnaround was complete last year.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.